Investing.com – U.S. stocks were lower after the close on Wednesday, as losses in the Telecoms, Utilities and Oil & Gas sectors led shares lower. At the close in NYSE, the Dow...
Q1 wasn’t a good period for the equity market overall, and the small-cap stocks. We could call Q1 a strange period as well. The small-cap Russell 2000 Index dropped more than...
Cigna Corporation (NYSE:CI) CI is set to report first-quarter 2021 results on May 7, before the opening bell.In the fourth quarter of 2020, the company’s earnings of $3.51...
Kodiak Sciences (NASDAQ:KOD) Inc. KOD announced that it has completed enrollment in the pivotal phase IIb/III DAZZLE study, which is evaluating its lead pipeline candidate KSI-301...
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company’s preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet inhibitor for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.